EAM Investors’s BioSpecifics Technologies Corp. BSTC Stock Holding History

EAM Investors’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-17,696	Closed	-$1.1M	–	333
2019 Q1	$1.1M	Hold	17,696	–	–	0.27%	168
2018 Q4	$1.07M	Buy	17,696 +1,328	+8%	+$79.3K	0.29%	161
2018 Q3	$957K	Buy	+16,368	New	+$835K	0.14%	227
2016 Q1	–	Sell	-111,866	Closed	-$4.81M	–	370
2015 Q4	$4.81M	Buy	111,866 +28,752	+35%	+$1.44M	0.63%	15
2015 Q3	$3.62M	Buy	83,114 +40,580	+95%	+$2.19M	0.57%	27
2015 Q2	$2.19M	Sell	42,534 -36,367	-46%	-$1.55M	0.26%	171
2015 Q1	$3.09M	Buy	78,901 +530	+0.7%	+$20.8K	0.36%	147
2014 Q4	$3.03M	Buy	78,371 +22,735	+41%	+$867K	0.42%	70
2014 Q3	$1.96M	Buy	+55,636	New	+$1.63M	0.4%	68

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's BSTC Position: Q2 2019 in Review

EAM Investors sold out of BioSpecifics Technologies Corp. (BSTC) in Q2 2019, closing a stake of 17,696 shares — an estimated $1.1M sold.

EAM Investors first reported a position in BSTC in Q3 2014 and held it in 9 quarters. The position peaked at $4.81M in Q4 2015. 114 funds tracked by Wall St. Rank hold BSTC as of Q2 2019.

EAM Investors reported no remaining BioSpecifics Technologies Corp. position as of Q2 2019 after selling out during the quarter.
EAM Investors sold 17,696 BioSpecifics Technologies Corp. shares in Q2 2019, an estimated $1.1M.
EAM Investors first reported a position in BioSpecifics Technologies Corp. in Q3 2014 and held it in 9 quarters.
EAM Investors's BioSpecifics Technologies Corp. position peaked at $4.81M in Q4 2015.
114 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q2 2019.

Based on EAM Investors's 13F filing for Q2 2019, filed 14 Aug 2019.